Nymox Receives Buy Recommendation with New Update by Cohen Independent Research Group.

HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that Cohen Independent Research Group has issued a "Buy" recommendation in newly written research coverage on the Company. The report is available at www.cohenresearch.com as well as from First Call, Bloomberg, and other leading providers.

The base case assumption of the report values NYMX at $7.20 per share with a target of $10.00. The 19 page report states, "We continue to rate Nymox Pharmaceutical Corp a "Buy"."

CIRG distributes and provides research and analyst coverage for selected companies with outstanding business models. The report can be accessed on CIRG's website: www.cohenresearch.com.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The above full report, including disclosures and disclaimers, is available at www.cohenresearch.com. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.